Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 321
Filter
1.
Ned Tijdschr Tandheelkd ; 131(1): 28-33, 2024 Jan.
Article in Dutch | MEDLINE | ID: mdl-38193355

ABSTRACT

Duchenne muscular dystrophy is a hereditary progressive neuromuscular disorder. Deterioration and weakening of the muscles is also present in orofacial muscles. Both weakness of the muscles and the fact that patients become more dependent of care, can make oral care more difficult. At this moment, it is unknown how patients with Duchenne muscular dystrophy experience their oral health and which problems regarding oral health and oral care may impact their oral health related quality of life. In this cross-sectional study, we found that, despite a high percentage of gingivitis, a high percentage of patients who experience halitosis and a high percentage of malocclusions, patients score their oral health related quality of life as good.


Subject(s)
Malocclusion , Muscular Dystrophy, Duchenne , Humans , Muscular Dystrophy, Duchenne/complications , Muscular Dystrophy, Duchenne/epidemiology , Oral Health , Cross-Sectional Studies , Quality of Life , Malocclusion/epidemiology
2.
Early Hum Dev ; 159: 105399, 2021 08.
Article in English | MEDLINE | ID: mdl-34126586

ABSTRACT

Nutritive sucking is a complex process, essential to proper growth and development. The complexity of this oral sensorimotor activity includes movements of the tongue and jaw. Tongue movements during nutritive sucking can only be visualized with instrumented methods such as ultrasound. Until now, studies using ultrasound during nutritive sucking performed measurements on each individual ultrasound image frame, which was quite time-consuming. The aim of this pilot study was to automatically process ultrasound video recordings in healthy infants during bottle feeding to measure teat compression and tongue movements. Tongue movements and teat compression during bottle feeding were visualized and recorded using 2D dynamic ultrasound imaging. A custom-made semi-automated analysis-routine was developed. Teat compression was expressed as the median difference in teat diameter during the recording. Tongue movements were expressed as the displacement of the tongue along four evenly distributed image lines and the corresponding time-shifts between those lines. The recordings of 12 out of 14 participants were adequate for the analysis of tongue movements. Teat compression could be analysed in the recordings of 6 participants. The reliability of our analysis-routine was considered to be good, and the analysis-routine was more time-efficient than manual frame-by-frame analysis. This quantitative analysis-routine is a promising tool, that can be used efficiently and accurately in the future to collect normative data that can serve as reference values to distinguish normal from abnormal tongue movements in infants with feeding difficulties.


Subject(s)
Bottle Feeding , Sucking Behavior , Breast Feeding , Female , Humans , Infant , Pilot Projects , Reproducibility of Results , Tongue/diagnostic imaging , Ultrasonography
3.
J Appl Microbiol ; 130(3): 707-721, 2021 Mar.
Article in English | MEDLINE | ID: mdl-32767832

ABSTRACT

AIMS: To describe the temporal trends in Escherichia coli pathotypes and antimicrobial resistance detected in isolates from diseased-pig cases submitted to the EcL from 2008 to 2016, in Quebec, Canada, and to investigate the presence of spatiotemporal and phylogenetic clusters. METHODS AND RESULTS: Detection of 12 genes coding for virulence factors in pathogenic E. coli in pigs by PCR and antimicrobial resistance standard disc diffusion assay were performed. Demographic and clinical data were entered in the Animal Pathogenic and Zoonotic E. coli (APZEC) database. ETEC:F4 was the most prevalent pathovirotype among the 3773 cases submitted. The LT:STb:F4 virotype was predominant until 2014, then was overtaken by the LT:STb:STa:F4 virotype. More than 90% of the ETEC:F4 isolates were multidrug resistant. A spatiotemporal cluster of LT:STb:STa:F4 isolates non-susceptible to enrofloxacin was detected between 4/2015 and 9/2016. Pulsed-field gel electrophoresis analysis of 137 ETEC:F4 isolates revealed the presence of a cluster composed mainly of LT:STb:STa:F4 isolates non-susceptible to enrofloxacin. CONCLUSIONS: The APZEC database was useful to highlight temporal trends in E. coli pathotypes. A high-risk ETEC:F4 clone might disseminate in the pig population in Quebec since 2015. SIGNIFICANCE AND IMPACT OF THE STUDY: Surveillance is crucial to identify new clones and develop control strategies.


Subject(s)
Drug Resistance, Multiple, Bacterial , Enrofloxacin/pharmacology , Enterotoxigenic Escherichia coli/classification , Enterotoxigenic Escherichia coli/drug effects , Escherichia coli Infections/veterinary , Swine Diseases/microbiology , Animals , Canada , Databases, Factual , Electrophoresis, Gel, Pulsed-Field , Enterotoxigenic Escherichia coli/isolation & purification , Enterotoxigenic Escherichia coli/pathogenicity , Escherichia coli Infections/microbiology , Phylogeny , Swine , Virulence Factors/genetics
4.
Article in English | MEDLINE | ID: mdl-33038835

ABSTRACT

Double lipoxygenation of polyunsaturated fatty acids having at least three methylene-interrupted double bonds can be made by two lipoxygenases, e.g. 5- and 12-LOX, or 15-LOX only, followed by reduction of the hydroperoxide products through the glutathione peroxidase action. Several biological activities have been reported for such a double 15-LOX product of docosahexaenoic acid, called protectin DX to differentiate it from protectin D1, a stereo and geometric isomer described for its potent anti-inflammatory potential. The geometric characteristic of the double lipoxygenase products is the conjugated triene E,Z,E (trans,cis,trans), which appears crucial in their biological activities. A focus is also done on single lipoxygenation of mono-hydroxylated products first made by aspirin-treated cyclooxygenase-2. The resulting (R,S)-diOH, E,Z,E conjugated trienes, instead of the (S,S)-diOH isomer in case of double lipoxygenation, seem to be even more active for some biological effects, making biologically relevant the single lipoxygenation in aspirin-treated situations.


Subject(s)
Fatty Acids, Unsaturated/metabolism , Lipoxygenases/metabolism , Animals , Humans
5.
BMC Pediatr ; 20(1): 44, 2020 Jan 30.
Article in English | MEDLINE | ID: mdl-32000741

ABSTRACT

Following the publication of the article [1], the authors noticed that Fig. 3 used is not the updated version. The correct version is shown below.

6.
BMC Pediatr ; 19(1): 477, 2019 12 05.
Article in English | MEDLINE | ID: mdl-31805974

ABSTRACT

BACKGROUND: Nutritive sucking is a complex activity, the biomechanical components of which may vary in relation to respiratory phase, swallow-rate per minute, suck-swallow ratio, and swallow non-inspiratory flow (SNIF). Quantitative measurement of these components during nutritive sucking in healthy infants could help us to understand the complex development of sucking, swallowing, and breathing. This is important because the coordination between these components is often disturbed in infants with feeding difficulties. The aims of this study were to describe the biomechanical components of sucking and swallowing in healthy 2- to 5-month-old infants during bottle feeding, to assess whether infants adapt to the characteristics of two different teats, and to determine which independent variables influence the occurrence of SNIF. METHODS: Submental muscle activity, nasal airflow, and cervical auscultation were evaluated during bottle-feeding with two different teats. RESULTS: Sixteen term-born infants (6 boys) aged 2-5 months were included. All infants showed variable inhalation and exhalation after swallowing. The swallow rate per minute was significantly higher when infants fed with a higher flow teat (Philips Avent Natural 2.0™). Infants had suck:swallow ratios ranging from 1:1 to 4:1. A suck:swallow ratio of 1:1 occurred significantly more often when infants fed with a higher flow teat, whereas a suck:swallow ratio of 2:1 occurred significantly more often when infants fed with a low-flow teat (Philips Avent Classic+™). A suck:swallow ratio of 1:1 was negatively correlated with SNIF, whereas a suck:swallow ratio of 2:1 was positively correlated with SNIF. CONCLUSION: Healthy infants aged 2-5 months can adapt to the flow, shape, and flexibility of different teats, showing a wide range of biomechanical and motor adaptations.


Subject(s)
Bottle Feeding/instrumentation , Deglutition/physiology , Respiratory Mechanics/physiology , Sucking Behavior/physiology , Cross-Sectional Studies , Equipment Design , Female , Humans , Infant , Male
7.
J Oral Rehabil ; 44(3): 155-162, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28054362

ABSTRACT

In patients with mitochondrial disease, fatigue and muscle problems are the most common complaints. They also experience these complaints during mastication. To measure endurance of continuous mastication in patients with mitochondrial diseases, the 6-min mastication test (6MMT) was developed. This study included the collection of normal data for the 6MMT in a healthy population (children and adults). During 6 min of continuous mastication on a chew tube chewing cycles per minute, total amount of chewing cycles and the difference between minute 1 (M1 ) and minute 6 (M2 ) were collected in 271 healthy participants (5-80 years old). These results were compared with those of nine paediatric and 25 adult patients with a mitochondrial disease. Visual analogue scale (VAS) scores were collected directly after the test and after 5 min. A qualitative rating was made on masticatory movements. The reproducibility of the 6MMT in the healthy population with an interval of approximately 2 weeks was good. The inter-rater reliability for the observations was excellent. The patient group demonstrated lower total amount of chewing cycles or had greater differences between M1 and M6 . The 6MMT is a reliable and objective test to assess endurance of continuous chewing. It demonstrates the ability of healthy children and adults to chew during 6 min with a highly stable frequency of mastication movements. The test may give an explanation for the masticatory problems in patient groups, who are complaining of pain and fatigue during mastication.


Subject(s)
Mastication/physiology , Mitochondrial Diseases/physiopathology , Muscle Fatigue/physiology , Physical Endurance/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Analysis of Variance , Bite Force , Chewing Gum , Child , Child, Preschool , Female , Healthy Volunteers , Humans , Male , Middle Aged , Movement , Netherlands , Reference Values , Reproducibility of Results , Young Adult
8.
Sex Transm Infect ; 93(2): 105-111, 2017 03.
Article in English | MEDLINE | ID: mdl-27535762

ABSTRACT

OBJECTIVES: To understand which aspects of general practitioner (GP) and HIV clinic appointments people living with HIV (PLWHIV) most value when seeking advice for new health problems. METHODS: A discrete choice experiment using a convenience sample of people diagnosed with HIV. Participants were recruited from 14 general HIV clinics in the South East of England between December 2014 and April 2015. ORs were calculated using conditional logit (CLOGIT) and latent class models (LCMs). RESULTS: A total of 1106 questionnaires were returned. Most participants were male (85%), white (74%) and were men who have sex with men (69%). The CLOGIT analysis showed people particularly valued shorter appointment waiting times (ORs between 1.52 and 3.62, p<0.001 in all instances). The LCM analysis showed there were two distinct classes, with 59% and 41% of respondents likely to be in each. The first class generally preferred GP to HIV clinic appointments and particularly valued 'being seen quickly'. For example, they had strong preferences for shorter appointment waiting times and longer GP opening hours. People in the second class also valued shorter waiting times, but they had a strong general preference for HIV clinic rather than GP appointments. CONCLUSIONS: PLWHIV value many aspects of care for new health problems, particularly short appointment waiting times. However, they appear split in their general willingness to engage with GPs.


Subject(s)
Choice Behavior , HIV Infections/therapy , Health Services Accessibility/statistics & numerical data , Health Services Research , Patient Preference/statistics & numerical data , Primary Health Care/statistics & numerical data , Appointments and Schedules , England , General Practice , HIV Infections/psychology , Humans , Patient Preference/psychology , Physician-Patient Relations , Surveys and Questionnaires
9.
Mol Psychiatry ; 22(9): 1313-1326, 2017 09.
Article in English | MEDLINE | ID: mdl-27184122

ABSTRACT

Hemizygous deletion of a 1.5- to 3-megabase region on chromosome 22 causes 22q11.2 deletion syndrome (22q11DS), which constitutes one of the strongest genetic risks for schizophrenia. Mouse models of 22q11DS have abnormal short-term synaptic plasticity that contributes to working-memory deficiencies similar to those in schizophrenia. We screened mutant mice carrying hemizygous deletions of 22q11DS genes and identified haploinsufficiency of Mrpl40 (mitochondrial large ribosomal subunit protein 40) as a contributor to abnormal short-term potentiation (STP), a major form of short-term synaptic plasticity. Two-photon imaging of the genetically encoded fluorescent calcium indicator GCaMP6, expressed in presynaptic cytosol or mitochondria, showed that Mrpl40 haploinsufficiency deregulates STP via impaired calcium extrusion from the mitochondrial matrix through the mitochondrial permeability transition pore. This led to abnormally high cytosolic calcium transients in presynaptic terminals and deficient working memory but did not affect long-term spatial memory. Thus, we propose that mitochondrial calcium deregulation is a novel pathogenic mechanism of cognitive deficiencies in schizophrenia.


Subject(s)
DiGeorge Syndrome/genetics , Nuclear Proteins/genetics , Animals , Calcium/metabolism , DiGeorge Syndrome/metabolism , Disease Models, Animal , Haploinsufficiency , Hippocampus/metabolism , Humans , Memory, Short-Term/physiology , Mice , Mitochondria/metabolism , Neuronal Plasticity/genetics , Neuronal Plasticity/physiology , Nuclear Proteins/metabolism , Presynaptic Terminals/metabolism , Ribonucleoproteins , Ribosomal Proteins , Schizophrenia/genetics
10.
BMC Health Serv Res ; 16(1): 677, 2016 11 30.
Article in English | MEDLINE | ID: mdl-27899106

ABSTRACT

BACKGROUND: Increasing numbers of people with HIV are living into older age and experiencing comorbidities. The development of new models of care to meet the needs of this population is now a priority. It is important that the views and preferences of patients inform the development of services in order to maintain high levels of patient satisfaction and engagement. The aim of this systematic review was to determine which aspects of healthcare are particularly valued by people living with HIV. METHODS: We searched electronic databases and reference lists of relevant articles. The search strategy was developed to identify articles reporting on HIV positive patients' perceptions, evaluations or experiences of healthcare services and factors associated with satisfaction with care. Peer-reviewed papers and conference abstracts were included if the study reported on aspects of health care that were valued by people living with HIV, data were collected during the era of combination therapy (from 1996 onwards), and the paper was published in English. A thematic approach to data synthesis was used. RESULTS: Twenty-three studies met the inclusion criteria. Studies used both qualitative and quantitative methods. Six studies specifically reported on relative importance to patients of different aspects of care. The valued aspects of care identified were grouped into seven themes. These highlighted the importance to patients of: a good health care professional-patient relationship, HIV specialist knowledge, continuity of care, ease of access to services, access to high quality information and support, effective co-ordination between HIV specialists and other healthcare professionals, and involvement in decisions about treatment and care. We were unable to determine the relative importance to patients of different aspects of care because of methodological differences between the studies. CONCLUSIONS: This review identified several attributes of healthcare that are valued by people living with HIV, many of which would be relevant to any future reconfiguration of services to meet the needs of an ageing population. Further research is required to determine the relative importance to patients of different aspects of care.


Subject(s)
Delivery of Health Care , HIV Infections/therapy , Patient Preference , Developed Countries , Health Services , Humans , Professional-Patient Relations
11.
AIDS Care ; 28(7): 834-41, 2016 07.
Article in English | MEDLINE | ID: mdl-26885765

ABSTRACT

Depression is a common but frequently undiagnosed feature in individuals with HIV infection. To find a strategy to detect depression in a non-specialized clinical setting, the overall performance of the Hospital Anxiety and Depression Scale (HADS) and the depression identification questions proposed by the European AIDS Clinical Society (EACS) guidelines were assessed in a descriptive cross-sectional study of 113 patients with HIV infection. The clinician asked the two screening questions that were proposed under the EACS guidelines and requested patients to complete the HADS. A psychiatrist or psychologist administered semi-structured clinical interviews to yield psychiatric diagnoses of depression (gold standard). A receiver operating characteristic (ROC) analysis for the HADS-Depression (HADS-D) subscale indicated that the best sensitivity and specificity were obtained between the cut-off points of 5 and 8, and the ROC curve for the HADS-Total (HADS-T) indicated that the best cut-off points were between 12 and 14. There were no statistically significant differences in the correlations of the EACS (considering positive responses to one [A] or both questions [B]), the HADS-D ≥ 8 or the HADS-T ≥ 12 with the gold standard. The study concludes that both approaches (the two EACS questions and the HADS-D subscale) are appropriate depression-screening methods in HIV population. We believe that using the EACS-B and the HADS-D subscale in a two-step approach allows for rapid, assumable and accurate clinical diagnosis in non-psychiatric hospital settings.


Subject(s)
Depression , HIV Infections , Mass Screening/methods , Adult , Comprehensive Health Care/methods , Cross-Sectional Studies , Depression/diagnosis , Depression/epidemiology , Depression/etiology , Female , HIV Infections/complications , HIV Infections/epidemiology , HIV Infections/psychology , Humans , Interview, Psychological/methods , Male , Middle Aged , ROC Curve , Sensitivity and Specificity , Spain/epidemiology
12.
Prog Lipid Res ; 60: 41-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26484703

ABSTRACT

Synthesis of bioactive oxygenated metabolites of polyunsaturated fatty acids and their degradation or transformation products are made through multiple enzyme processes. The kinetics of the enzymes responsible for the different steps are known to be quite diverse, although not precisely determined. The location of the metabolites biosynthesis is diverse as well. Also, the biological effects of the primary and secondary products, and their biological life span are often completely different. Consequently, phenotypes of cells in response to these bioactive lipid mediators must then depend on their concentrations at a given time. This demands a fluxolipidomics approach that can be defined as a mediator lipidomics, with all measurements done as a function of time and biological compartments. This review points out what is known, even qualitatively, in the blood vascular compartment for arachidonic acid metabolites and number of other metabolites from polyunsaturated fatty acids of nutritional value. The functional consequences are especially taken into consideration.


Subject(s)
Fatty Acids, Unsaturated/blood , Fatty Acids, Unsaturated/chemistry , Oxygen/metabolism , Blood Platelets/metabolism , Endothelial Cells/metabolism , Fatty Acids, Unsaturated/metabolism , Humans , Leukocytes/metabolism , Metabolic Flux Analysis , Oxygen/blood
13.
J Vet Intern Med ; 29(6): 1707-11, 2015.
Article in English | MEDLINE | ID: mdl-26289543

ABSTRACT

BACKGROUND: The identification of serum biomarkers of lung inflammation would facilitate the diagnosis of inflammatory airway disease (IAD) in horses. HYPOTHESIS: Horses with IAD have higher serum concentrations of markers of inflammation compared to controls. ANIMALS: Twelve horses with IAD and 10 control horses. METHODS: This was a prospective case-control study. Blood and BALF were collected from horses with IAD and controls. Serum concentration of surfactant protein D (SP-D), haptoglobin, serum amyloid A (SAA) and of the soluble form of triggering receptor expressed on myeloid cells 1 (sTREM-1) was measured using commercial ELISA tests. RESULTS: Horses with IAD had higher serum concentration (log-transformed values) of SP-D (mean ± SD: 1.773 ± 0.51), haptoglobin (6.657 ± 0.202) and SAA (0.128 ± 0.396) compared to controls (0.942 ± 0.226, 6.38 ± 0.22, -0.398 ± 0.319, respectively; P < .01 for all). Furthermore, the concentrations of SP-D and haptoglobin combined allowed differentiating the 2 groups (IAD: 8.43 ± 0.564, controls: 7.322 ± 0.249, P < .0001) with a sensitivity and specificity of 100% when a cut-off of 7.70 (log value) was employed. CONCLUSIONS AND CLINICAL IMPORTANCE: Surfactant protein D and haptoglobin serum concentrations could be a diagnostic aid in IAD. Further studies are necessary to establish the specificity of our findings before they can be applied in everyday practice.


Subject(s)
Haptoglobins/metabolism , Horse Diseases/blood , Inflammation/veterinary , Pulmonary Surfactant-Associated Protein D/blood , Respiratory Tract Diseases/veterinary , Animals , Biomarkers , Bronchoalveolar Lavage Fluid/chemistry , Case-Control Studies , Female , Gene Expression Regulation , Haptoglobins/chemistry , Horse Diseases/diagnosis , Horses , Inflammation/blood , Inflammation/metabolism , Male , Pulmonary Surfactant-Associated Protein D/chemistry , Pulmonary Surfactant-Associated Protein D/metabolism , Respiratory Tract Diseases/blood , Respiratory Tract Diseases/metabolism
16.
Thromb Haemost ; 114(2): 289-96, 2015 Aug.
Article in English | MEDLINE | ID: mdl-25832443

ABSTRACT

Platelets from patients with type 2 diabetes are characterised by hyperactivation and high level of oxidative stress. Docosahexaenoic acid (DHA) may have beneficial effects on platelet reactivity and redox status. We investigated whether moderate DHA supplementation, given as a triglyceride form, may correct platelet dysfunction and redox imbalance in patients with type 2 diabetes. We conducted a randomised, double-blind, placebo-controlled, two-period crossover trial (n=11 post-menopausal women with type 2 diabetes) to test the effects of 400 mg/day of DHA intake for two weeks on platelet aggregation, markers of arachidonic acid metabolism, lipid peroxidation status, and lipid composition. Each two week-period was separated from the other by a six-week washout. Daily moderate dose DHA supplementation resulted in reduced platelet aggregation induced by collagen (-46.5 %, p< 0.001), and decreased platelet thromboxane B2 (-35 %, p< 0.001), urinary 11-dehydro-thromboxane B2 (-13.2 %, p< 0.001) and F2-isoprostane levels (-19.6 %, p< 0.001) associated with a significant increase of plasma and platelet vitamin E concentrations (+20 % and +11.8 %, respectively, p< 0.001). The proportions of DHA increased both in plasma lipids and in platelet phospholipids. After placebo treatment, there was no effect on any parameters tested. Our findings support a significant beneficial effect of low intake of DHA on platelet function and a favourable role in reducing oxidative stress associated with diabetes.


Subject(s)
Antioxidants/therapeutic use , Blood Platelets/drug effects , Diabetes Mellitus, Type 2/drug therapy , Dietary Supplements , Docosahexaenoic Acids/therapeutic use , Lipids/blood , Oxidative Stress/drug effects , Administration, Oral , Antioxidants/pharmacology , Arachidonic Acid/metabolism , Blood Platelets/chemistry , Collagen/pharmacology , Cross-Over Studies , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/urine , Dinoprost/analogs & derivatives , Dinoprost/blood , Docosahexaenoic Acids/pharmacology , Dose-Response Relationship, Drug , Double-Blind Method , F2-Isoprostanes/urine , Fatty Acids/blood , Female , Humans , Lipid Peroxidation/drug effects , Membrane Lipids/blood , Middle Aged , Phospholipids/blood , Platelet Aggregation/drug effects , Postmenopause , Thromboxane B2/analogs & derivatives , Thromboxane B2/blood , Thromboxane B2/urine , alpha-Tocopherol/blood
17.
Article in English | MEDLINE | ID: mdl-24582148

ABSTRACT

1-acetyl,2-docosahexaenoyl-glycerophosphocholine (AceDoPC) has been made to prevent docosahexaenoyl (DHA) to move to the sn-1 position as it rapidly does when present in 1-lyso,2-docosahexaenoyl-GPC (lysoPC-DHA), an efficient DHA transporter to the brain. When incubated with human blood, AceDoPC behaves closer to lysoPC-DHA than PC-DHA in terms of binding to plasma albumin and lipoproteins, and DHA incorporation into platelets and red cells. In addition, AceDoPC prevents more efficiently the deleterious effects of the experimental stroke in rats than does unesterified DHA. Also, AceDoPC inhibits platelet-activating factor-induced human blood platelet aggregation. Overall, AceDoPC might act as an efficient DHA transporter to the brain, and as a neuro-protective agent by itself.


Subject(s)
Brain/metabolism , Neuroprotective Agents/therapeutic use , Phosphatidylcholines/therapeutic use , Phospholipids/metabolism , Animals , Brain/drug effects , Brain/pathology , Humans , Neuroprotective Agents/pharmacology , Phosphatidylcholines/pharmacology , Stroke/drug therapy
18.
Equine Vet J ; 46(4): 474-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24423012

ABSTRACT

REASONS FOR PERFORMING STUDY: Bronchospasm results in airway obstruction in horses with heaves. Atropine is the most potent bronchodilator drug currently available for horses, but is associated with side effects that limit its use. Like atropine, N-butylscopolammonium bromide (NBB) is an anticholinergic agent with bronchodilatory properties. OBJECTIVES: To compare the bronchodilating effects and side effects of atropine and NBB in horses with heaves. STUDY DESIGN: Cross-over experiment using horses with heaves. METHODS: Eight horses with heaves were administered atropine and NBB, using a cross-over design. Heart rate, pupillary dilatation, transrectal palpation, lung mechanics (maximal changes in transpulmonary pressure, pulmonary resistance and elastance) and arterial blood gases were assessed before and 10 and 30 min after drug administration. RESULTS: One horse treated with atropine developed colic. Significant pupillary dilatation was observed only with atropine. Tachycardia developed in all horses, but was more marked with atropine. Lung function improved with both drugs, but elastance values had returned to baseline at 30 min with NBB. There was no improvement in arterial hypoxaemia with either drug. CONCLUSIONS: The study indicated that the bronchodilatory properties of NBB were not statistically different from those of atropine, but were of shorter duration. N-butylscopolammonium bromide was associated with fewer systemic side effects, and therefore NBB should be preferred over atropine when assessing the reversibility of airway obstruction in horses.


Subject(s)
Atropine/adverse effects , Bronchoconstriction/drug effects , Butylscopolammonium Bromide/adverse effects , Horse Diseases/drug therapy , Lung Diseases, Obstructive/veterinary , Parasympatholytics/adverse effects , Animals , Atropine/therapeutic use , Butylscopolammonium Bromide/therapeutic use , Cross-Over Studies , Female , Horses , Lung Diseases, Obstructive/drug therapy , Male , Parasympatholytics/therapeutic use
19.
J Antimicrob Chemother ; 68(6): 1423-30, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23404193

ABSTRACT

OBJECTIVES: A high proportion of patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia die within a few days of the onset of infection. However, predictive factors for early mortality (EM) have barely been examined. The aim of this study was to determine the predictive factors for EM in patients with MRSA bacteraemia. METHODS: All episodes of MRSA bacteraemia were prospectively followed in 21 Spanish hospitals from June 2008 to December 2009. Epidemiology, clinical data, therapy and outcome were recorded. All MRSA strains were analysed in a central laboratory. Mortality was defined as death from any cause occurring in the 30 days after the onset of MRSA bacteraemia. EM was defined as patients who died within the first 2 days, and late mortality (LM) for patients who died after this period. Multivariate analyses were performed by using logistic regression models. RESULTS: A total of 579 episodes were recorded. Mortality was observed in 179 patients (31%): it was early in 49 (8.5%) patients and late in 130 (22.5%). Independent risk factors for EM were [OR (95% CI)] initial Pitt score >3 [3.99 (1.72-3.24)], previous rapid fatal disease [3.67 (1.32-10.24)], source of infection lower respiratory tract or unknown [3.76 (1.31-10.83) and 2.83 (1.11-7.21)], non-nosocomial acquisition [2.59 (1.16-5.77)] and inappropriate initial antibiotic therapy [3.59 (1.63-7.89)]. When predictive factors for EM and LM were compared, inappropriate initial antibiotic therapy was the only distinctive predictor of EM, while endocarditis and lower respiratory tract sources both predicted LM. CONCLUSIONS: In our large cohort of patients several factors were related to EM, but the only distinctive predictor of EM was inappropriate initial antibiotic therapy.


Subject(s)
Bacteremia/mortality , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/mortality , Age Factors , Aged , Bacteremia/microbiology , Cohort Studies , Drug Resistance, Bacterial , Female , Humans , Logistic Models , Male , Methicillin-Resistant Staphylococcus aureus/drug effects , Microbial Sensitivity Tests , Middle Aged , Predictive Value of Tests , Risk Factors , Sex Factors , Staphylococcal Infections/microbiology , Treatment Outcome
20.
Article in English | MEDLINE | ID: mdl-22520055

ABSTRACT

Docosahexaenoic acid (DHA) is known as a major nutrient from marine origin. Considering its beneficial effect in vascular risk prevention, the effect of DHA on blood components, especially platelets, will be reviewed here. Investigating the dose-effect of DHA in humans shows that daily intake lower than one gram/day brings several benefits, such as inhibition of platelet aggregation, resistance of monocytes against apoptosis, and reinforced antioxidant status in platelets and low-density lipoproteins. However, higher daily intake may be less efficient on those parameters, especially by losing the antioxidant effect. On the other hand, a focus on the inhibition of platelet aggregation by lipoxygenase end-products of DHA is made. The easy conversion of DHA by lipoxygenases and the formation of a double lipoxygenation product named protectin DX, reveal an original way for DHA to contribute in platelet inhibition through both the cyclooxygenase inhibition and the antagonism of thromboxane A2 action.


Subject(s)
Antioxidants/metabolism , Blood Platelets/metabolism , Dietary Supplements , Docosahexaenoic Acids/metabolism , Oxidants/metabolism , Animals , Antioxidants/administration & dosage , Antioxidants/adverse effects , Antioxidants/therapeutic use , Dietary Supplements/adverse effects , Docosahexaenoic Acids/administration & dosage , Docosahexaenoic Acids/adverse effects , Docosahexaenoic Acids/therapeutic use , Humans , Lipid Peroxidation , Lipoproteins, LDL/blood , Lipoproteins, LDL/metabolism , Lipoxygenases/metabolism , Oxidants/administration & dosage , Oxidants/adverse effects , Oxidants/therapeutic use , Platelet Aggregation , Platelet Aggregation Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/adverse effects , Platelet Aggregation Inhibitors/metabolism , Platelet Aggregation Inhibitors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...